Press Kit: Brand-to-Generic Patent Cliff 2026
Dataset summary
- Scope: 50 high-volume US prescription drugs across 24 therapeutic categories
- Time range: Patent expiry years 1982 through 2026; cash-price snapshots Q1-Q2 2026
- Geographic scope: United States; FDA Orange Book and Drugs@FDA primary references
- Method: Cross-reference of FDA Orange Book, Drugs@FDA, CMS NADAC public file, GoodRx public listings, Cost Plus Drugs catalog, GAO and ASPE drug pricing reports, and IQVIA Use of Medicines public data
- License: CC-BY 4.0; full dataset and aggregates available as machine-readable JSON
- Lead author: Vincent, RxGrab Research (Editorial Review Pending)
Five quotable findings
"The typical generic launch cuts the cash price by 85 percent within 24 months of first competition, but five blockbusters in our cohort, Ozempic, Wegovy, Jardiance, Eliquis, and Xarelto, are still brand-only in 2026 and carry combined US sales above 55 billion dollars. The next major patent cliff sits squarely on the GLP-1 and anticoagulant markets."
Attribute to: Vincent, RxGrab Research, in the 2026 Brand-to-Generic Patent Cliff Audit
"Generic competition only works when there are at least four ANDA holders. Single-source generics charge roughly 3.4 times more than markets with four or more competitors. The fourth competitor is the inflection point, not the first."
Attribute to: Vincent, RxGrab Research
"Sixteen percent of the generics in our audit are stalled cases. The post-generic price stayed within 50 percent of brand for over a year after first launch. Albuterol HFA, Suboxone, Cialis, and Advair Diskus are textbook examples. The driver is almost always single-source ANDA, REMS programs, or device-drug combination complexity."
Attribute to: Vincent, RxGrab Research
"Mark Cuban Cost Plus Drugs is on average 67 percent cheaper than the GoodRx coupon-low price on the 32 generics that list on both. The retail-pharmacy plus discount-card stack is still operating well above the marginal cost of dispensing for many high-volume oral solids. The implication for payers is that direct sourcing arrangements have measurable headroom."
Attribute to: Vincent, RxGrab Research
"The median time from FDA patent expiry to first generic launch is 11 months, but the slowest 10 percent waited four years or longer. Citizen petitions, REMS, patent thickets, and device-drug combination disputes are the documented mechanisms. Every year of delay on a 5-billion-dollar brand preserves roughly 4 billion in revenue versus the post-generic counterfactual."
Attribute to: Vincent, RxGrab Research
Downloads
- Full study (HTML): rxgrab.com/research/brand-to-generic-patent-cliff-2026
- Open dataset (JSON): data.json [CC-BY 4.0]
- Companion stats page: 85 Prescription Drug Pricing Statistics 2026
- Methodology PDF: [PDF-PENDING] (available on request via media contact below)
- Full chart pack (PNG + SVG): [CHART-PACK-PENDING] (available on request)
- Source records: RxGrab drug pricing database
Republish & Embed the headline chart
Free to embed under CC-BY 4.0 with link attribution to the study page. The embedded chart includes the YMYL disclaimer banner; please do not strip it.
<iframe src="https://rxgrab.com/research/brand-to-generic-patent-cliff-2026/embed/price-drop-distribution.html" width="100%" height="440" frameborder="0" loading="lazy" title="Brand-to-generic cash-price drop distribution across 45 prescription drugs, RxGrab 2026"></iframe>CC-BY 4.0, please link to the source study when republishing. The embedded chart includes the disclaimer banner (not medical advice); please do not strip it.
Targeted press contacts
This study is shaped for prescription-pricing and drug-channel reporters. Specific outlets we have prepared the briefing for:
- KFF Health News · Drug pricing investigative desk
- STAT · Pharma pricing and policy beat (Adam Cancryn / Ed Silverman desks)
- Drug Channels Institute · Adam Fein, channel and pricing analytics
- Endpoints News · Generic and biosimilar coverage
- Pharmaceutical Executive · Brand strategy and patent strategy
- ProPublica health desk · Drug pricing investigations
Media contact
Vincent, RxGrab Research
Email: [email protected] [PRESS-EMAIL-PENDING]
Available for: written quotes (24 hour turnaround), data drill-down requests, podcast or video interview, on-record commentary on patent cliff timing, generic substitution economics, stalled-generic mechanisms, Mark Cuban Cost Plus Drugs price benchmarking, and Inflation Reduction Act negotiated prices in context.
Response time: typically same-day during ET business hours.
About RxGrab
RxGrab is an independent prescription drug pricing research site at rxgrab.com. We publish first-party pharmacy comparisons, drug-pricing audits, and decision-shaped guides for uninsured, underinsured, and Medicare-Part-D patients. RxGrab is part of the DeepSynthesis Lattice, a constellation of niche research sites covering ecommerce, finance, education, and health verticals.